North Carolina Marketplace Laboratory Testing Policies
- F2019: Flow Cytometry – Effective Date:01-01-2023
- G2002: Cervical Cancer Screening – Effective Date:01-01-2023
- G2005: Vitamin D Testing – Effective Date: 01-01-2023
- G2006: Hemoglobin A1c – Effective Date:01-01-2023
- G2007: Prostate Biopsies – Effective Date:01-01-2023
- G2008: Prostate Specific Antigen Testing – Effective Date:01-01-2023
- G2009: Preventive Screening In Adults – Effective Date:01-01-2023
- G2011: Diagnostic Testing of Iron Homeostasis & Metabolism – Effective Date:01-01-2023
- G2013: Testosterone Testing – Effective Date:01-01-2023
- G2014: Vitamin B12 And Methylmalonic Acid Testing – Effective Date:01-01-2023
- G2022: ANA/ENA Testing – Effective Date:01-01-2023
- G2031: Allergen Testing – Effective Date:01-01-2023
- G2035: Prenatal Screening (Nongenetic) – Effective Date:01-01-2023
- G2036: Hepatitis C – Effective Date: 01-01-2023
- G2042: Pediatric Preventive Screening – Effective Date:01-01-2023
- G2043: Celiac Disease Testing – Effective Date:01-01-2023
- G2044: Helicobacter pylori Testing – Effective Date:01-01-2023
- G2045: Thyroid Disease Testing – Effective Date:01-01-2023
- G2048: Biochemical Markers Of Alzheimer Disease and Dementia – Effective Date:01-01-2023
- G2050: Cardiovascular Disease Risk Assessment – Effective Date:01-01-2023
- G2051: Bone Turnover Markers Testing – Effective Date:01-01-2023
- G2055: Prenatal Screening for Fetal Aneuploidy – Effective Date:01-01-2023
- G2056: Diagnosis of Idiopathic Environmental Intolerance – Effective Date:01-01-2023
- G2059: Epithelial Cell Cytology In Breast Cancer Risk Assessment – Effective Date:01-01-2023
- G2060: Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing – Effective Date: 01-01-2023
- G2061: Fecal Calprotectin Testing – Effective Date:01-01-2023
- G2063: Testing for Diagnosis of Active or Latent Tuberculosis – Effective Date:01-01-2023
- G2098: Immune Cell Function Assay – Effective Date:01-01-2023
- G2099: Intracellular Micronutrient Analysis – Effective Date:01-01-2023
- G2100: In Vitro Chemoresistance And Chemosensitivity Assays – Effective Date:01-01-2023
- G2105: Immunopharmacologic Monitoring of Therapeutic Serum Antibodies – Effective Date:01-01-2023
- G2107: Measurement Of Thromboxane Metabolites For ASA Resistance – Effective Date:01-01-2023
- G2110: Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease – Effective Date:01-01-2023
- G2113: Oral Screening Lesion Identification Systems and Genetic Screening – Effective Date: 01-01-2023
- G2115: Metabolite Markers For Thiopurines Testing – Effective Date:01-01-2023
- G2119: Diagnostic Testing of Influenza – Effective Date:01-01-2023
- G2120: Salivary Hormone Testing – Effective Date:01-01-2023
- G2121: Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease – Effective Date:01-01-2023
- G2123: Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases – Effective Date:01-01-2023
- G2124: Serum Tumor Markers for Malignancies – Effective Date:01-01-2023
- G2125: Urinary Tumor Markers for Bladder Cancer – Effective Date:01-01-2023
- G2127: Vectra DA Blood Test for Rheumatoid Arthritis – Effective Date:01-01-2023
- G2130: ST2 Assay for Chronic Heart Failure – Effective Date:01-01-2023
- G2133: ZIKA Virus Risk Assessment – Effective Date:01-01-2023
- G2138: Evaluation of Dry Eyes – Effective Date:01-01-2023
- G2143: Lyme Disease – Effective Date:01-01-2023
- G2149: Pathogen Panel Testing – Effective Date:01-01-2023
- G2150: Cardiac Biomarkers for Myocardial Infarction – Effective Date:01-01-2023
- G2153: Pancreatic Enzyme Testing for Acute Pancreatitis – Effective Date:01-01-2023
- G2154: Folate Testing – Effective Date:01-01-2023
- G2155: General Inflammation Testing – Effective Date:01-01-2023
- G2156: Urine Culture Testing for Bacteria – Effective Date:01-01-2023
- G2157: Diagnostic Testing Of Common Sexually Transmitted Infections – Effective Date:01-01-2023
- G2158: Testing for Mosquito- or Tick-Related Infections – Effective Date:01-01-2023
- G2159: B-Hemolytic Streptococcus Testing – Effective Date:01-01-2023
- G2164: Parathyroid Hormone Phosphorus Calcium and Magnesium Testing – Effective Date:01-01-2023
- G2173: Gamma-glutamyl Transferase – Effective Date:01-01-2023
- G2174: Coronavirus Testing in the Outpatient Setting – Effective Date:01-01-2023
- M2041: Venous and Arterial Thrombosis Risk Testing – Effective Date:01-01-2023
- M2057: Diagnosis of Vaginitis including Multi-target PCR Testing – Effective Date:01-01-2023
- M2058: Genetic Testing for Adolescent Idiopathic Scoliosis – Effective Date: 01-01-2023
- M2068: Testing for Alpha-1 Antitrypsin Deficiency – Effective Date:01-01-2023
- M2093: HIV Genotyping and Phenotyping – Effective Date:01-01-2023
- M2097: Identification of Microorganisms Using Nucleic Acid Probes – Effective Date:01-01-2023
- M2112: Nerve Fiber Density Testing – Effective Date:01-01-2023
- M2116: Plasma HIV-1 and HIV-2 RNA Quantification for HIV Infection – Effective Date:01-01-2023
- M2141: Testing of Homocysteine Metabolism-Related Conditions – Effective Date:01-01-2023
- M2172: Onychomycosis Testing – Effective Date:01-01-2023
- M2176: Testing for Autism Spectrum Disorder and Developmental Delay – Effective Date:01-01-2023
- P2018: Immunohistochemistry – Effective Date:01-01-2023
- R2162: Avalon Laboratory Procedures Reimbursement Policy – Effective Date:01-01-2023
- T2015: Prescription Medication and Illicit Drug Testing in the Outpatient Setting – Effective Date:01-01-2023